The function and clinical utility of stem cell markers in metastatic castration-resistant prostate cancer (mCRPC) remains unresolved and their expression may confer important therapeutic opportunities for staging and therapy. manifestation of CD133 in circulating tumor cells (CTCs) from patients with mCRPC and to test JNJ 42153605 the hypothesis that patients with mCRPC had CD133-positive CTCs… Continue reading The function and clinical utility of stem cell markers in metastatic